The role of xanthine oxidoreductase and uric acid in metabolic syndrome.

[1]  G. Mancia,et al.  Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study , 2018, Journal of hypertension.

[2]  M. Lanaspa,et al.  Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. , 2018, International journal of cardiology.

[3]  Sabine Weiskirchen,et al.  Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease , 2017, Front. Immunol..

[4]  T. Ye,et al.  Xanthine dehydrogenase downregulation promotes TGFβ signaling and cancer stem cell-related gene expression in hepatocellular carcinoma , 2017, Oncogenesis.

[5]  N. Ishizaka,et al.  Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients , 2017, PloS one.

[6]  C. Borghi,et al.  Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study , 2017, Annals of medicine.

[7]  M. Lanaspa,et al.  Perspective: A Historical and Scientific Perspective of Sugar and Its Relation with Obesity and Diabetes. , 2017, Advances in nutrition.

[8]  Y. Moriwaki,et al.  Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans. , 2017, Metabolism: clinical and experimental.

[9]  Dong-Mei Zhang,et al.  High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions , 2017, Nutrients.

[10]  M. Lanaspa,et al.  Dietary and commercialized fructose: Sweet or sour? , 2017, International Urology and Nephrology.

[11]  C. Borghi,et al.  An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia , 2017, Vascular health and risk management.

[12]  T. Asano,et al.  Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis , 2016, Mediators of inflammation.

[13]  Usama A A Sharaf El Din,et al.  Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review , 2016, Journal of advanced research.

[14]  R. Holmdahl,et al.  Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis. , 2016, Free radical biology & medicine.

[15]  L. Polito,et al.  Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a 
Detoxifying Enzyme , 2016, Current medicinal chemistry.

[16]  M. Harma,et al.  Is Xanthine oxidase activity in polycystic ovary syndrome associated with inflammatory and cardiovascular risk factors? , 2016, Journal of reproductive immunology.

[17]  Carolina Muscoli,et al.  Regulation of uric acid metabolism and excretion. , 2016, International journal of cardiology.

[18]  S. Anker,et al.  Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications. , 2016, International journal of cardiology.

[19]  M. Lanaspa,et al.  Uric acid in metabolic syndrome: From an innocent bystander to a central player. , 2016, European journal of internal medicine.

[20]  A. Okawa,et al.  Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis. , 2016, Biochemical and biophysical research communications.

[21]  M. Kuwabara.  Hyperuricemia, Cardiovascular Disease, and Hypertension , 2016, Pulse.

[22]  M. Romão,et al.  Structure and function of mammalian aldehyde oxidases , 2016, Archives of Toxicology.

[23]  L. Polito,et al.  Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects , 2015, Oxidative medicine and cellular longevity.

[24]  L. Polito,et al.  Xanthine oxidoreductase in cancer: more than a differentiation marker , 2015, Cancer medicine.

[25]  S. Sharma,et al.  Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia , 2015, Journal of Investigative Medicine.

[26]  D. Granger,et al.  Reperfusion injury and reactive oxygen species: The evolution of a concept☆ , 2015, Redox biology.

[27]  M. Becker,et al.  Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease , 2015, Current medical research and opinion.

[28]  N. Abraham,et al.  Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity , 2015, Stem cells international.

[29]  E. Kelley.  A new paradigm for XOR-catalyzed reactive species generation in the endothelium , 2015, Pharmacological reports : PR.

[30]  H. Shaltout,et al.  Allopurinol alleviates hypertension and proteinuria in high fructose, high salt and high fat induced model of metabolic syndrome. , 2015, Translational research : the journal of laboratory and clinical medicine.

[31]  Takeshi Nishino,et al.  The C‐terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidase , 2015, The FEBS journal.

[32]  L. Roberts.  Does inorganic nitrate say NO to obesity by browning white adipose tissue? , 2015, Adipocyte.

[33]  Yaw-Wen Chang,et al.  Relationship between Hyperuricemia and Lipid Profiles in US Adults , 2015, BioMed research international.

[34]  L. Polito,et al.  Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. , 2014, Atherosclerosis.

[35]  G. Desideri,et al.  New Insight into Urate-Related Mechanism of Cardiovascular Damage. , 2014, Current pharmaceutical design.

[36]  L. Polito,et al.  Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. , 2014, Biochimica et biophysica acta.

[37]  A. Schürmann,et al.  Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9 , 2014, Nature Communications.

[38]  D. Mikhailidis,et al.  Uric acid metabolism in pre-hypertension and the metabolic syndrome. , 2014, Current vascular pharmacology.

[39]  M. Lotze,et al.  S100A4 and Uric Acid Promote Mesenchymal Stromal Cell Induction of IL-10+/IDO+ Lymphocytes , 2014, The Journal of Immunology.

[40]  M. Lanaspa,et al.  Uric acid‐dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  A. So,et al.  Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice , 2014, Scientific Reports.

[42]  Yong Wu,et al.  PTEN phosphorylation and nuclear export mediate free fatty acid-induced oxidative stress. , 2014, Antioxidants & redox signaling.

[43]  D. Feig.  Serum uric acid and the risk of hypertension and chronic kidney disease , 2014, Current opinion in rheumatology.

[44]  S. Chadban,et al.  Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study , 2013, BMC Cardiovascular Disorders.

[45]  E. Kelley,et al.  Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how. , 2013, Nitric oxide : biology and chemistry.

[46]  S. Tannenbaum,et al.  Chemistry meets biology in colitis-associated carcinogenesis , 2013, Free radical research.

[47]  T. Funahashi,et al.  Uric Acid Secretion from Adipose Tissue and Its Increase in Obesity* , 2013, The Journal of Biological Chemistry.

[48]  G. Vilahur,et al.  Mechanisms of Chronic State of Inflammation as Mediators That Link Obese Adipose Tissue and Metabolic Syndrome , 2013, Mediators of inflammation.

[49]  E. Kelley,et al.  Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation☆ , 2013, Redox biology.

[50]  M. Caulfield,et al.  Enhanced Vasodilator Activity of Nitrite in Hypertension: Critical Role for Erythrocytic Xanthine Oxidoreductase and Translational Potential , 2013, Hypertension.

[51]  Kai Huang,et al.  High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort Studies , 2013, PloS one.

[52]  R. Wright,et al.  Contribution of uric acid to cancer risk, recurrence, and mortality , 2012, Clinical and Translational Medicine.

[53]  L. Tamariz,et al.  Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. , 2012, Congestive heart failure.

[54]  M. Severo,et al.  Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome , 2012, Endocrine.

[55]  D. Pašalić,et al.  Uric acid as one of the important factors in multifactorial disorders – facts and controversies , 2012, Biochemia medica.

[56]  R. Terkeltaub,et al.  Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. , 2012, Arthritis and rheumatism.

[57]  J. Masrour-Roudsari,et al.  Role of oxidative stress in pathogenesis of metabolic syndrome , 2012, Caspian journal of internal medicine.

[58]  H. Song,et al.  Interaction between serum uric acid and triglycerides in relation to blood pressure , 2011, Journal of Human Hypertension.

[59]  M. Lanaspa,et al.  Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations. , 2011, Seminars in nephrology.

[60]  C. Baylis,et al.  Hyperuricemia as a Mediator of the Proinflammatory Endocrine Imbalance in the Adipose Tissue in a Murine Model of the Metabolic Syndrome , 2011, Diabetes.

[61]  Y. Chan,et al.  Is uric acid protective or deleterious in acute ischemic stroke? A prospective cohort study. , 2010, Atherosclerosis.

[62]  V. Micheli,et al.  Pediatric neurological syndromes and inborn errors of purine metabolism , 2010, Neurochemistry International.

[63]  P. Higgins,et al.  The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular Disease , 2009, Cardiovascular Psychiatry and Neurology.

[64]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[65]  Satoru Kodama,et al.  Association Between Serum Uric Acid and Development of Type 2 Diabetes , 2009, Diabetes Care.

[66]  G. Şener,et al.  Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome , 2008, Clinical Research in Cardiology.

[67]  T. Nakagawa,et al.  Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. , 2008, American journal of physiology. Renal physiology.

[68]  M. Fratelli,et al.  Mammalian aldehyde oxidases: genetics, evolution and biochemistry , 2008, Cellular and Molecular Life Sciences.

[69]  I. Édes,et al.  High-fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion. , 2006, American journal of physiology. Heart and circulatory physiology.

[70]  D. Mikhailidis,et al.  Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? , 2006, Metabolism: clinical and experimental.

[71]  Takahiko Nakagawa,et al.  A causal role for uric acid in fructose-induced metabolic syndrome. , 2006, American journal of physiology. Renal physiology.

[72]  S. Grundy,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[73]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[74]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[75]  S. Grundy,et al.  The metabolic syndrome , 2003, The Lancet.

[76]  K. Tuttle,et al.  Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? , 2003, Hypertension.

[77]  D. Harrison,et al.  Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure: Role of Xanthine-Oxidase and Extracellular Superoxide Dismutase , 2002, Circulation.

[78]  T. Nakagawa,et al.  Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. , 2002, Hypertension.

[79]  Hirotaka Matsuo,et al.  Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.

[80]  B. Freeman,et al.  Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. , 1993, Free radical biology & medicine.

[81]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[82]  K. Raivio,et al.  FRUCTOSE-INDUCED HYPERURICÆMIA , 1967 .

[83]  D. Berkowitz.  BLOOD LIPID AND URIC ACID INTERRELATIONSHIPS. , 1964, JAMA.

[84]  M. Griffiths.  The mechanism of the diabetogenic action of uric acid. , 1950, The Journal of biological chemistry.

[85]  M. Lanaspa,et al.  Uric Acid as a Cause of the Metabolic Syndrome. , 2018, Contributions to nephrology.

[86]  M. Lanaspa,et al.  Uric Acid Is a Strong Risk Marker for Developing Hypertension From Prehypertension: A 5-Year Japanese Cohort Study , 2018, Hypertension.

[87]  J. Klenk,et al.  Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 men. , 2009, Annals of epidemiology.

[88]  P. Holvoet.  Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. , 2008, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

[89]  D. Moller,et al.  Metabolic syndrome: a clinical and molecular perspective. , 2005, Annual review of medicine.

[90]  渡辺 励.  Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity , 2004 .

[91]  G. Zalba,et al.  [Vascular oxidative stress and endothelial dysfunction]. , 2001, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[92]  K. Raivio,et al.  Fructose-induced hyperuricaemia. , 1967, Lancet.